Shareholding for the Period Ended March 31, 2017
Alembic Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here11-04-2017
11-04-2017
Compliance Certificate Pursuant To Regulation 7 (3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dear Sir / Madam, With reference to the captioned subject, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is a SEBI approved category-I, Registrar & Transfer Agent, registered with Securities and Exchange Board of India (SEBI Registration Number : INR000004058). For Alembic...10-04-2017
Statement Regarding Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Quarter Ended 31St March, 2017
With reference to the captioned subject, we enclose herewith investor complaints as per Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 31st March, 2017. We request you to kindly take the same on record. Thanking you. Yours faithfully, For Alembic Limited Drigesh Mittal Dy. Company Secretary07-04-2017
Alembic Limited Q3 results show marginal revenue growth
Alembic reported revenue growth of 9% YoY to record a total of Rs. 30.6 crore in income for the quarter ended December 2016. The firm also reversed from losses in last year's Q3 to marginal profits of Rs. 0.6 crore for Q3 this year. Institutional investor shareholding has declined in Alembic from 9.04% to 8.83% in the December quarter.23-01-2017
Outcome of Board Meeting
Alembic Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 19, 2017, inter alia, has taken the following decisions:1. Approved the resignation of Mr. Udit Amin from the position of Managing Director of the Company w.e.f. January 31, 2017 (after close of business hours). Mr. Udit Amin will continue as an Non-Executive Director, liable to retire by rotation....19-01-2017
Standalone Financial Results, Limited Review Report for December 31, 2016
Alembic Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 201619-01-2017
Board Meeting Intimation for Results & Closure of Trading Window
Alembic Ltd has informed BSE that a Meeting of Board of Directors of the Company shall be held on January 19, 2017, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months period ended on December 31, 2016.Further, the trading window shall remain closed from January 16, 2017 to January 21, 2017 for the above purpose.11-01-2017
Shareholding for the Period Ended December 31, 2016
Alembic Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here09-01-2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Alembic Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.07-01-2017
Alembic receives USFDA approval for Itraconazole capsules
Itraconazole capsules had an estimated market size of $42 million for twelve months ending December 201516-12-2016